Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biomea Fusion (BMEA – Research Report) and GoodRx Holdings (GDRX – Research Report).
Biomea Fusion (BMEA)
In a report released today, Robyn Karnauskas from Truist Financial assigned a Buy rating to Biomea Fusion, with a price target of $55.00. The company’s shares closed last Monday at $15.30.
According to TipRanks.com, Karnauskas is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biomea Fusion with a $49.38 average price target, representing a 221.7% upside. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $50.00 price target.
See the top stocks recommended by analysts >>
GoodRx Holdings (GDRX)
In a report released today, Jailendra Singh from Truist Financial maintained a Hold rating on GoodRx Holdings. The company’s shares closed last Monday at $7.10.
According to TipRanks.com, Singh is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on GoodRx Holdings is a Moderate Buy with an average price target of $8.88.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BMEA:
- Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
- Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
- Largest borrow rate increases among liquid names
- Biomea Fusion options imply 6.2% move in share price post-earnings
